Nuvation Bio Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for NUVB, updated each market day.
NUVB AI Sentiment
AI predicts Nuvation Bio Inc. stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Sector
Exchange
Market Cap
$1,609,375,448
Cap Tier
Employees
298
Headquarters
NEW YORK, NY
Listed Since
Feb. 10, 2021
Website
NUVB Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
NUVB Volatility
Nuvation Bio Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
